# PTPN18

## Overview
PTPN18, or protein tyrosine phosphatase non-receptor type 18, is a gene that encodes a phosphatase enzyme involved in the regulation of various cellular signaling pathways. The protein product of PTPN18 is characterized as a non-receptor type phosphatase, which plays a crucial role in modulating tyrosine phosphorylation states within cells. This regulation is essential for controlling processes such as cell growth, differentiation, and migration. PTPN18 is particularly significant in the context of HER2-related signaling, where it influences the phosphorylation and ubiquitination of the HER2 receptor, thereby affecting its stability and degradation. The protein's structural features, including a catalytic domain and a PEST domain, facilitate its interactions with substrates and other proteins, impacting cellular homeostasis and signaling dynamics (Wang2014The; Tong2021Molecular). PTPN18's involvement in various cancers, such as breast, endometrial, and colorectal cancer, underscores its clinical significance, where it can function as either a tumor suppressor or promoter depending on the cellular context (Wang2014The; Cai2019Downregulation; Li2021PTPN18).

## Structure
PTPN18, also known as BDP1, is a protein tyrosine phosphatase involved in HER2-related signaling pathways. The protein consists of a phosphatase catalytic domain located in the N-terminal region and a noncatalytic domain in the C-terminal region (Tong2021Molecular). The catalytic domain features an α/β structure with approximately 280 amino acid residues, including a 'PTP1B-like' accessible pocket that accommodates phosphotyrosine (pY) at the +1 position (Tong2021Molecular). Key structural elements contributing to substrate specificity include the pY binding loop (residues 60-67), the β3 strand (residues 126-129), and the β4 strand (residues 152-154) (Tong2021Molecular).

PTPN18 has a unique hydrophobic pocket that favors hydrophobic pY+1 residues, which is crucial for its substrate selectivity (Wang2014The). The protein's side-chain plasticity, particularly of residue R198, allows it to recognize different peptide conformations, forming hydrogen bonds and hydrophobic interactions with HER2 peptide residues (Wang2014The). The PEST domain in the C-terminal region plays a role in HER2 ubiquitination, recruiting the E3 ligase β-Trcp for proteasomal degradation (Wang2014The). The structural dynamics of PTPN18, including the movement of the WPD loop upon binding with phospho-peptides, are critical for its function (Tong2021Molecular).

## Function
PTPN18, also known as protein tyrosine phosphatase non-receptor type 18, is a phosphatase that plays a significant role in regulating signaling pathways in human cells. It is involved in the dephosphorylation of tyrosine residues on target proteins, which is crucial for modulating various cellular processes. In erythroid progenitor cells, PTPN18 acts as a positive regulator of the EPOR/JAK2 signaling pathway. This regulation enhances the proliferation and survival of these cells by sustaining the activation of key signaling molecules such as ERK1/2, AKT, STAT5, and JAK2. PTPN18 also influences the levels of high molecular weight forms of the erythropoietin receptor (EPOR) and modulates the phosphorylation of the EPOR-associated adaptor protein, RHEX (Held2020PhosphoPTM).

In the context of HER2 signaling, PTPN18 specifically targets and dephosphorylates certain tyrosine residues on the HER2 receptor, impacting cell growth and migration. It also regulates HER2 ubiquitination and degradation, acting as a switch between lysosomal and proteasomal degradation pathways. This dual role in phosphorylation and ubiquitination is essential for maintaining cellular homeostasis and signaling, particularly in processes related to cell proliferation and invasion (Wang2014The).

## Clinical Significance
PTPN18 has been implicated in the progression of several cancers due to alterations in its expression levels and interactions. In breast cancer, PTPN18 is involved in regulating HER2 phosphorylation and ubiquitination, with its expression levels correlating with cancer stage. A higher HER2/PTPN18 ratio is observed in stage III compared to stage II breast cancer, suggesting that changes in PTPN18 expression may contribute to cancer progression (Wang2014The). PTPN18 also acts as a tumor suppressor in breast cancer by inhibiting metastasis through its nuclear import, which is facilitated by MVP and importin β2. Downregulation of PTPN18 is associated with increased metastatic potential and poorer prognosis (Wang2022Nuclear).

In endometrial cancer, PTPN18 is overexpressed, and its silencing leads to reduced proliferation and metastasis, indicating its role in promoting cancer progression (Cai2019Downregulation). Similarly, in colorectal cancer, PTPN18 expression is increased and associated with enhanced tumor growth and poorer survival outcomes, suggesting its involvement in cancer development through the c-myc-cdk4 axis (Li2021PTPN18). These findings highlight the dual role of PTPN18 in different cancer types, acting as both a tumor suppressor and promoter depending on the context.

## Interactions
PTPN18 interacts with several proteins, playing a significant role in various cellular processes. In breast cancer, PTPN18 is involved in the nuclear import process facilitated by importin β2 and MVP, where it interacts with these proteins to regulate its localization. This interaction is crucial for its role in inhibiting epithelial-mesenchymal transition (EMT) and metastasis by dephosphorylating and promoting the degradation of ETS1, a transcriptional activator involved in these processes (Wang2022Nuclear).

PTPN18 also interacts with HER2, a receptor tyrosine kinase, by dephosphorylating specific phosphorylation sites, such as pY 1112, pY 1196, and pY 1248. These interactions influence HER2's phosphorylation and ubiquitination, affecting its stability and degradation. PTPN18 promotes K48-linked polyubiquitination and proteasomal degradation of HER2, particularly through interactions with c-Cbl and β-Trcp, which are involved in HER2 ubiquitination (Wang2014The).

In colorectal cancer, PTPN18 interacts with the MYC protein, stabilizing its levels and promoting the MYC-CDK4 axis, which is crucial for cell cycle progression and cancer cell proliferation (Li2021PTPN18). Additionally, PTPN18 is involved in EPO-modulated signaling pathways, interacting with the EPOR/JAK2 signaling complex and affecting the phosphorylation of RHEX (Held2020PhosphoPTM).


## References


[1. (Wang2014The) Hong-Mei Wang, Yun-Fei Xu, Shang-Lei Ning, Du-Xiao Yang, Yi Li, Yu-Jie Du, Fan Yang, Ya Zhang, Nan Liang, Wei Yao, Ling-Li Zhang, Li-Chuan Gu, Cheng-Jiang Gao, Qi Pang, Yu-Xin Chen, Kun-Hong Xiao, Rong Ma, Xiao Yu, and Jin-Peng Sun. The catalytic region and pest domain of ptpn18 distinctly regulate the her2 phosphorylation and ubiquitination barcodes. Cell Research, 24(9):1067–1090, August 2014. URL: http://dx.doi.org/10.1038/cr.2014.99, doi:10.1038/cr.2014.99. This article has 64 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/cr.2014.99)

[2. (Li2021PTPN18) Chao Li, Shang-Ze Li, Xi-Cheng Huang, Jie Chen, Wenbin Liu, Xiao-Dong Zhang, Xue-Min Song, and Run-Lei Du. Ptpn18 promotes colorectal cancer progression by regulating the c-myc-cdk4 axis. Genes &amp; Diseases, 8(6):838–848, November 2021. URL: http://dx.doi.org/10.1016/j.gendis.2020.08.001, doi:10.1016/j.gendis.2020.08.001. This article has 12 citations.](https://doi.org/10.1016/j.gendis.2020.08.001)

[3. (Wang2022Nuclear) Tao Wang, Xinlei Ba, Xiaonan Zhang, Na Zhang, Guowen Wang, Bin Bai, Tong Li, Jiahui Zhao, Yanjiao Zhao, Yang Yu, and Bing Wang. Nuclear import of ptpn18 inhibits breast cancer metastasis mediated by mvp and importin β2. Cell Death &amp; Disease, August 2022. URL: http://dx.doi.org/10.1038/s41419-022-05167-z, doi:10.1038/s41419-022-05167-z. This article has 9 citations.](https://doi.org/10.1038/s41419-022-05167-z)

[4. (Cai2019Downregulation) Junhong Cai, Sizhe Huang, Yuping Yi, and Shan Bao. Downregulation of <scp>ptpn</scp>18 can inhibit proliferation and metastasis and promote apoptosis of endometrial cancer. Clinical and Experimental Pharmacology and Physiology, 46(8):734–742, May 2019. URL: http://dx.doi.org/10.1111/1440-1681.13098, doi:10.1111/1440-1681.13098. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/1440-1681.13098)

[5. (Held2020PhosphoPTM) Matthew A. Held, Emily Greenfest-Allen, Su Su, Christian J. Stoeckert, Matthew P. Stokes, and Don M. Wojchowski. Phospho-ptm proteomic discovery of novel epo- modulated kinases and phosphatases, including ptpn18 as a positive regulator of epor/jak2 signaling. Cellular Signalling, 69:109554, May 2020. URL: http://dx.doi.org/10.1016/j.cellsig.2020.109554, doi:10.1016/j.cellsig.2020.109554. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2020.109554)

[6. (Tong2021Molecular) Mingqiong Tong, Peng Liu, Wan Sun, Jing Liu, Na Fan, Xiaoyue Wang, Zhongyu Zhang, Xinfeng Song, Chao Lv, and Yan Wang. Molecular dynamics simulation studies on the specific regulation of <scp>ptpn18</scp> to the <scp>her2</scp> phospho‐peptides. Journal of Molecular Recognition, February 2021. URL: http://dx.doi.org/10.1002/jmr.2890, doi:10.1002/jmr.2890. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jmr.2890)